MYLK2

Chr 20ADDigenic dominant

myosin light chain kinase 2

Also known as: KMLC, MLCK, MLCK2, skMLCK

This gene encodes a calcium/calmodulin-dependent myosin light chain kinase that phosphorylates myosin light chains to regulate muscle contraction and cardiac function, with exclusive expression in adult skeletal muscle. Mutations cause hypertrophic cardiomyopathy through digenic inheritance, meaning pathogenic variants in this gene work together with variants in another gene to cause disease. The gene shows moderate constraint against loss-of-function variants (LOEUF 0.477), and there is a GeneReviews entry available for additional clinical guidance.

Summary from RefSeq, OMIM, UniProt
Research Assistant →

Primary Disease Associations & Inheritance

Cardiomyopathy, hypertrophic, 1, digenicMIM #192600
ADDigenic dominant
UniProtCardiomyopathy, familial hypertrophic
0
Active trials
7
Pubs (1 yr)
9
P/LP submissions
0%
P/LP missense
0.48
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryMYLK2
🧬
Gene-Disease Validity (ClinGen)
hypertrophic cardiomyopathy · ADDisputed

Disputed — evidence questions this relationship

Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.24) despite low pLI — interpret in context.
📋
ClinVar Variants
9 unique Pathogenic / Likely Pathogenic· 265 VUS of 501 total submissions
📖
GeneReview available — MYLK2
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint
0.48LOEUF
pLI 0.233
Z-score 3.50
OE 0.24 (0.130.48)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint
0.23Z-score
OE missense 0.97 (0.881.06)
325 obs / 336.6 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.24 (0.130.48)
00.351.4
Missense OE0.97 (0.881.06)
00.61.4
Synonymous OE1.04
01.21.6
LoF obs/exp: 6 / 24.8Missense obs/exp: 325 / 336.6Syn Z: -0.34
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
limitedMYLK2-related hypertrophic cardiomyopathyOTHERAD
DN
0.6355th %ile
GOF
0.7126th %ile
LOF
0.4135th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

501 submitted variants in ClinVar

Classification Summary

Pathogenic6
Likely Pathogenic3
VUS265
Likely Benign187
Benign10
Conflicting23
6
Pathogenic
3
Likely Pathogenic
265
VUS
187
Likely Benign
10
Benign
23
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
6
0
6
Likely Pathogenic
0
0
3
0
3
VUS
14
226
23
2
265
Likely Benign
0
8
73
106
187
Benign
0
0
7
3
10
Conflicting
23
Total14234112111494

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

MYLK2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC